摘要
肝细胞癌(hepatocellular carcinoma,HCC)是人类最常见的恶性肿瘤之一,具有恶性程度高、病死率高及预后差等特点.HCC确诊时多数已处于晚期,究其原因关键是缺乏高敏感性及特异性的早期诊断分子标志物.miRNA(microRNA)是真核生物中一类参与基因转录后水平调控的非编码小分子单链RNA,其对肿瘤生长发育、细胞分化、增殖和凋亡等生命活动用重要的调节作用.而血清miRNA的异常表达与HCC密切相关,其作为新兴的肿瘤分子标志物对于HCC的临床诊断、疗效监测及预后评估具有重要的应用价值.
HepatoceIIular carcinoma （HCC） is one of the most common malignant tumors, with features of high malignancy, high mortality and poor prognosis. Most patients with HCC are diag- nosed at late stages. One main reason is the lack of highly sensitive and specific molecular mark- ers. MicroRNAs （miRNA） are a kind of small non-coding RNAs involved in posttranscrip- tional regulation in eukaryotes. They partici- pate in many developmental and physiological processes, including growth, cell differentiation, proliferation and apoptosis. Since abnormal ex- pression of miRNAs is closely related to HCC, serum miRNAs have appreciable value in early diagnosis, efficacy assessment and prognostic evaluation in HCC.
出处
《世界华人消化杂志》
CAS
北大核心
2014年第6期782-787,共6页
World Chinese Journal of Digestology
关键词
血清miRNA
肝细胞癌
早期诊断
疗效监测
预后评估
Serum miRNA
Hepatocellular carcino-ma
Early diagnosis
Efficacy
Prognostic evaluation
